IL246643B - תכשירים וערכות לטיפול בנגיף כשל חיסוני/תסמונת כשל חיסוני נרכשת - Google Patents

תכשירים וערכות לטיפול בנגיף כשל חיסוני/תסמונת כשל חיסוני נרכשת

Info

Publication number
IL246643B
IL246643B IL246643A IL24664316A IL246643B IL 246643 B IL246643 B IL 246643B IL 246643 A IL246643 A IL 246643A IL 24664316 A IL24664316 A IL 24664316A IL 246643 B IL246643 B IL 246643B
Authority
IL
Israel
Prior art keywords
accquired
kits
compositions
treating human
immunodeficiency virus
Prior art date
Application number
IL246643A
Other languages
English (en)
Other versions
IL246643A0 (he
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of IL246643A0 publication Critical patent/IL246643A0/he
Publication of IL246643B publication Critical patent/IL246643B/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL246643A 2014-01-08 2016-07-06 תכשירים וערכות לטיפול בנגיף כשל חיסוני/תסמונת כשל חיסוני נרכשת IL246643B (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461924936P 2014-01-08 2014-01-08
PCT/US2015/010658 WO2015105999A1 (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Publications (2)

Publication Number Publication Date
IL246643A0 IL246643A0 (he) 2016-08-31
IL246643B true IL246643B (he) 2020-02-27

Family

ID=53494410

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246643A IL246643B (he) 2014-01-08 2016-07-06 תכשירים וערכות לטיפול בנגיף כשל חיסוני/תסמונת כשל חיסוני נרכשת

Country Status (12)

Country Link
US (3) US10272143B2 (he)
EP (1) EP3091990B1 (he)
JP (1) JP6557240B2 (he)
KR (1) KR102503400B1 (he)
CN (1) CN105899219B (he)
AU (1) AU2015204770B2 (he)
BR (1) BR112016015736B1 (he)
CA (1) CA2936086C (he)
IL (1) IL246643B (he)
PH (1) PH12016501359A1 (he)
SG (2) SG10201908048QA (he)
WO (1) WO2015105999A1 (he)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150305983A1 (en) * 2009-11-20 2015-10-29 The University Of Versailles Saint-Quentin-En- Yvelines Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
US20190069528A1 (en) * 2016-03-21 2019-03-07 The George Washington University Engineered human hookworms as a novel biodelivery system for vaccines and biologicals
CA3089848A1 (en) * 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
USD1001795S1 (en) 2019-10-01 2023-10-17 Microsoft Corporation Computing device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
HUP0202734A3 (en) * 1999-05-04 2003-11-28 Schering Corp Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
AU2004269379A1 (en) 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic HIV compositions and related methods
KR20070019635A (ko) * 2003-08-28 2007-02-15 더 임뮨 리스판스 코포레이션 면역원성 hiv 조성물 및 이와 관련된 방법
HUE028467T2 (en) * 2004-02-26 2016-12-28 Immunovative Therapies Ltd A method for producing T-cells for cell therapy
EP3202895A1 (en) * 2004-03-01 2017-08-09 Immunovative Therapies, Ltd. A composition for use in cell therapy and methods for its preparation
US8043619B2 (en) 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
WO2010051521A1 (en) 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
KR20200063262A (ko) 2010-04-13 2020-06-04 이뮤노베이티브 테라피스, 엘티디. 조절 t 세포들의 저해를 위한 방법 및 조성물
US8686218B2 (en) 2010-04-14 2014-04-01 The Penn State Research Foundation Strategies for the transgenic manipulation of filamentous fungi

Also Published As

Publication number Publication date
BR112016015736B1 (pt) 2022-01-04
US10272143B2 (en) 2019-04-30
CA2936086C (en) 2024-02-27
JP6557240B2 (ja) 2019-08-07
US20150190488A1 (en) 2015-07-09
SG10201908048QA (en) 2019-10-30
US20200368334A1 (en) 2020-11-26
CN105899219A (zh) 2016-08-24
EP3091990B1 (en) 2021-05-12
KR20160124096A (ko) 2016-10-26
PH12016501359A1 (en) 2016-08-22
BR112016015736A2 (he) 2017-08-08
EP3091990A1 (en) 2016-11-16
WO2015105999A1 (en) 2015-07-16
AU2015204770B2 (en) 2020-07-02
CN105899219B (zh) 2021-08-13
KR102503400B1 (ko) 2023-02-23
CA2936086A1 (en) 2015-07-16
US20180200348A1 (en) 2018-07-19
US10729754B2 (en) 2020-08-04
JP2017502058A (ja) 2017-01-19
AU2015204770A1 (en) 2016-08-18
SG11201605440TA (en) 2016-08-30
EP3091990A4 (en) 2017-10-04
IL246643A0 (he) 2016-08-31

Similar Documents

Publication Publication Date Title
IL247309A0 (he) תכשירים לאיון שכפול של וירוס ושיטות להכנה ושימוש שלהם
HK1243640A1 (zh) 用於治療潰瘍的方法和組合物
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
IL286265A (he) נגיף אמנון חדש ושימושיו
IL273932A (he) שיטות לטיפול ומניעת הדבקה ויראלית
EP3209298A4 (en) Compositions and methods for treating insomnia
IL246879A0 (he) תכשירים של אפילימוד ושיטות לשימוש בהם
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
IL251108A0 (he) תכשירים ושיטות לטיפול בתסמונת קרינה חריפה
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
EP3166637A4 (en) Compositions and methods for treating dengue virus infection
EP3204426A4 (en) Compositions and methods for treating viral hemorrhagic fever
HK1246206A1 (zh) 用於治療青光眼的組合物和方法
EP3220908A4 (en) Compositions and methods for treating endometriosis
IL246643A0 (he) תכשירים וערכות לטיפול בנגיף כשל חיסוני/תסמונת כשל חיסוני נרכשת
PL3096625T3 (pl) Kompozycje przeciw kiełkowaniu do powlekania cebul i bulw oraz ich zastosowanie do traktowania przeciw kiełkowaniu
EP2969006A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFECTION WITH IMMUNODEFICIENCY VIRUSES
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
PL3397270T3 (pl) Kompozycje do zastosowania w leczeniu zespołu huntera
EP3122190A4 (en) Compositions and related methods for treating and preventing viral and retroviral infections
EP3197465A4 (en) Compositions and methods for treating a viral infection
EP3397271A4 (en) COMPOSITIONS AND METHOD FOR TREATING RETINOPATHY
GB201521083D0 (en) Compositions for treatment and methods thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed